1. HOME
2. Research Insight
3. Biosimilars Market Share - Global Industry Landscape

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. The growth of this market is mainly driven by rising demand for biosimilars in developed and developing countries, favorable reimbursement policies and launch of novel biosimilars in the market.

As of recent years, the biosimilars market has been experiencing significant growth driven by several factors such as patent expirations of originator biologics, increasing demand for cost-effective biologic therapies, and supportive regulatory frameworks.

To know about the assumptions considered for the study download the pdf brochure

Biosimilars Market Share:

• Key Players:
  • The biosimilars market is led by several key players, including multinational pharmaceutical companies and specialized biosimilar manufacturers.
  • Major players include Sandoz (a division of Novartis), Pfizer, Mylan (now Viatris), Teva Pharmaceutical Industries, Amgen, and Samsung Bioepis, among others.
• Therapeutic Areas:
  • Biosimilar products are available across various therapeutic areas, including oncology, autoimmune diseases, diabetes, growth disorders, and infectious diseases.
  • The oncology segment accounts for a significant share of the biosimilars market, with biosimilar versions of drugs like trastuzumab, rituximab, and bevacizumab being widely used.
• Geographic Distribution:
  • The biosimilars market is geographically diverse, with significant uptake observed in regions such as North America, Europe, Asia-Pacific, and Latin America.
  • Europe has been a major market for biosimilars, driven by supportive regulatory policies and early adoption by healthcare systems.
• Market Penetration:
  • Biosimilars have achieved varying levels of market penetration across different therapeutic areas and regions.
  • Factors influencing market penetration include pricing strategies, reimbursement policies, physician acceptance, patient preference, and competition from originator biologics.

Future Growth Expectations and Forecasts:

• Market Size and Growth Rate:
  • The biosimilars market is expected to experience robust growth in the coming years, fueled by factors such as patent expirations of originator biologics, increasing demand for cost-effective therapies, and expanding regulatory approvals.
  • Market research reports project the biosimilars market to grow at a compound annual growth rate (CAGR) ranging from high single digits to double digits over the forecast period.
• Drivers of Growth:
  • Patent Expirations: Expired patents on blockbuster biologics create opportunities for biosimilar manufacturers to enter the market with lower-cost alternatives, driving market growth.
  • Regulatory Support: Clear regulatory pathways for biosimilar approval provided by agencies such as the FDA (United States) and EMA (Europe) facilitate market entry and competition.
  • Increasing Acceptance: Growing acceptance of biosimilars among healthcare providers, payers, and patients as safe and effective alternatives to originator biologics contributes to market expansion.
  • Market Expansion: Emerging markets in Asia-Pacific, Latin America, and other regions are witnessing increasing uptake of biosimilars, driven by improving healthcare infrastructure and rising demand for biologic therapies.
• Opportunities and Challenges:
  • Opportunities: Continued innovation in biosimilar development and manufacturing, strategic partnerships and collaborations, expansion into new therapeutic areas, and geographic markets offer growth opportunities for biosimilar manufacturers.
  • Challenges: Complex manufacturing processes, regulatory hurdles, pricing pressures, concerns about interchangeability and immunogenicity, and competition from originator biologics pose challenges to biosimilar market growth.
• Investment and Expansion:
  • Increased investment in research and development, manufacturing capabilities, regulatory compliance, education, and market access strategies will be crucial for biosimilar manufacturers to capitalize on growth opportunities and overcome challenges.

In summary, the biosimilars market is poised for significant growth in the coming years, driven by factors such as patent expirations, regulatory support, increasing acceptance, and market expansion. Success in the biosimilars market will depend on the ability of manufacturers to innovate, navigate regulatory landscapes, address challenges, and seize emerging opportunities.

Related Reports:

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028